Single-cell Omics Market Size, Share, and Trends 2024 to 2033

Single-cell Omics Market (By Product: Single-Cell Genomics, Single-Cell Proteomics, Single-Cell Metabolomics, Single-Cell Transcriptomics; By Application: Immunology, Cell Biology, Oncology, Neurology; By End-User: Hospital and Diagnostic Laboratories, Academic and Research Organizations, Pharmaceutical & Biotechnology Companies) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : April 2024
  • Report Code : 2871
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Single-cell Omics Market 

5.1. COVID-19 Landscape: Single-cell Omics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Single-cell Omics Market, By Product

8.1. Single-cell Omics Market, by Product, 2024-2033

8.1.1 Single-Cell Genomics

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Single-Cell Proteomics

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Single-Cell Metabolomics

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Single-Cell Transcriptomics

8.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Single-cell Omics Market, By Application

9.1. Single-cell Omics Market, by Application, 2024-2033

9.1.1. Immunology

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Cell Biology

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Oncology

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Neurology

9.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Single-cell Omics Market, By End-User 

10.1. Single-cell Omics Market, by End-User, 2024-2033

10.1.1. Hospital and Diagnostic Laboratories

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Academic and Research Organizations

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Pharmaceutical & Biotechnology Companies

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Single-cell Omics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Product (2021-2033)

11.1.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.3. Market Revenue and Forecast, by End-User (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.4.3. Market Revenue and Forecast, by End-User (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.5.3. Market Revenue and Forecast, by End-User (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.3. Market Revenue and Forecast, by End-User (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.4.3. Market Revenue and Forecast, by End-User (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.5.3. Market Revenue and Forecast, by End-User (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.6.3. Market Revenue and Forecast, by End-User (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.7.3. Market Revenue and Forecast, by End-User (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.3. Market Revenue and Forecast, by End-User (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.4.3. Market Revenue and Forecast, by End-User (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.5.3. Market Revenue and Forecast, by End-User (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.6.3. Market Revenue and Forecast, by End-User (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.7.3. Market Revenue and Forecast, by End-User (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.3. Market Revenue and Forecast, by End-User (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.4.3. Market Revenue and Forecast, by End-User (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.5.3. Market Revenue and Forecast, by End-User (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.6.3. Market Revenue and Forecast, by End-User (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.7.3. Market Revenue and Forecast, by End-User (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.5.3. Market Revenue and Forecast, by End-User (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.5.4.3. Market Revenue and Forecast, by End-User (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.5.5.3. Market Revenue and Forecast, by End-User (2021-2033)

Chapter 12. Company Profiles

12.1. 1CellBio

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Celsee, Inc

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. QIAGEN N.V

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Illumina, Inc

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. 10X Genomics, Inc

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. GE LifeSciences 

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Mission Bio

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Takara Bio

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Fluidigm Corporation

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Bio-Rad Laboratories, Inc

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client